|
1
|
Roupret M, Zigeuner R, Palou J, et al:
European guidelines for the diagnosis and management of upper
urinary tract urothelial cell carcinomas: 2011 update. Eur Urol.
59:584–594. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stewart GD, Bariol SV, Grigor KM, Tolley
DA and McNeill SA: A comparison of the pathology of transitional
cell carcinoma of the bladder and upper urinary tract. BJU Int.
95:791–793. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li CC, Chang TH, Wu WJ, et al: Significant
predictive factors for prognosis of primary upper urinary tract
cancer after radical nephroureterectomy in Taiwanese patients. Eur
Urol. 54:1127–1134. 2008. View Article : Google Scholar
|
|
4
|
Hall MC, Womack JS, Roehrborn CG, Carmody
T and Sagalowsky AI: Advanced transitional cell carcinoma of the
upper urinary tract: patterns of failure, survival and impact of
postoperative adjuvant radiotherapy. J Urol. 160:703–706. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Munoz JJ and Ellison LM: Upper tract
urothelial neoplasms: incidence and survival during the last 2
decades. J Urol. 164:1523–1525. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ozsahin M, Zouhair A, Villa S, et al:
Prognostic factors in urothelial renal pelvis and ureter tumours: a
multicentre Rare Cancer Network study. Eur J Cancer. 35:738–743.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Papatsoris AG, Chrisofos M, Skolarikos A,
et al: Upper urinary tract transitional cell carcinoma. A 10-year
experience. Tumori. 94:75–78. 2008.PubMed/NCBI
|
|
8
|
Wu MH, Ma WL, Hsu CL, et al: Androgen
receptor promotes hepatitis B virus-induced hepatocarcinogenesis
through modulation of hepatitis B virus RNA transcription. Sci
Transl Med. 2:32ra352010.PubMed/NCBI
|
|
9
|
Miyamoto H, Yang Z, Chen YT, et al:
Promotion of bladder cancer development and progression by androgen
receptor signals. J Natl Cancer Inst. 99:558–568. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma WL, Hsu CL, Wu MH, et al: Androgen
receptor is a new potential therapeutic target for the treatment of
hepatocellular carcinoma. Gastroenterology. 135:947–955. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Himelstein BP, Canete-Soler R, Bernhard
EJ, Dilks DW and Muschel RJ: Metalloproteinases in tumor
progression: the contribution of MMP-9. Invasion Metastasis.
14:246–258. 1994.PubMed/NCBI
|
|
12
|
Kupferman ME, Fini ME, Muller WJ, Weber R,
Cheng Y and Muschel RJ: Matrix metalloproteinase 9 promoter
activity is induced coincident with invasion during tumor
progression. Am J Pathol. 157:1777–1783. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Riento K and Ridley AJ: Rocks:
multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol.
4:446–456. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schmitz AA, Govek EE, Bottner B and Van
Aelst L: Rho GTPases: signaling, migration, and invasion. Exp Cell
Res. 261:1–12. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sahai E and Marshall CJ: Differing modes
of tumour cell invasion have distinct requirements for Rho/ROCK
signalling and extracellular proteolysis. Nat Cell Biol. 5:711–719.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Itoh K, Yoshioka K, Akedo H, Uehata M,
Ishizaki T and Narumiya S: An essential part for Rho-associated
kinase in the transcellular invasion of tumor cells. Nat Med.
5:221–225. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kamai T, Kawakami S, Koga F, et al: RhoA
is associated with invasion and lymph node metastasis in upper
urinary tract cancer. BJU Int. 91:234–238. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miyata Y, Kanda S, Nomata K, Hayashida Y
and Kanetake H: Expression of metalloproteinase-2,
metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in
transitional cell carcinoma of upper urinary tract: correlation
with tumor stage and survival. Urology. 63:602–608. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Inoue K, Kamada M, Slaton JW, et al: The
prognostic value of angiogenesis and metastasis-related genes for
progression of transitional cell carcinoma of the renal pelvis and
ureter. Clin Cancer Res. 8:1863–1870. 2002.PubMed/NCBI
|
|
20
|
Delella FK, Justulin LA Jr and Felisbino
SL: Finasteride treatment alters MMP-2 and −9 gene expression and
activity in the rat ventral prostate. Int J Androl. 33:e114–e122.
2010.PubMed/NCBI
|
|
21
|
Hara T, Miyazaki H, Lee A, Tran CP and
Reiter RE: Androgen receptor and invasion in prostate cancer.
Cancer Res. 68:1128–1135. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schmidt LJ, Duncan K, Yadav N, et al: RhoA
as a mediator of clinically relevant androgen action in prostate
cancer cells. Mol Endocrinol. 26:716–735. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wolff H, Saukkonen K, Anttila S,
Karjalainen A, Vainio H and Ristimaki A: Expression of
cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58:4997–5001.
1998.PubMed/NCBI
|
|
24
|
Tsujii M, Kawano S and DuBois RN:
Cyclooxygenase-2 expression in human colon cancer cells increases
metastatic potential. Proc Natl Acad Sci USA. 94:3336–3340. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Osterlund KL, Handa RJ and Gonzales RJ:
Dihydrotestosterone alters cyclooxygenase-2 levels in human
coronary artery smooth muscle cells. Am J Physiol Endocrinol Metab.
298:E838–E845. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tzeng CC, Liu HS, Li C, et al:
Characterization of two urothelium cancer cell lines derived from a
blackfoot disease endemic area in Taiwan. Anticancer Res.
16:1797–1804. 1996.PubMed/NCBI
|
|
27
|
Ma WL, Hsu CL, Yeh CC, et al: Hepatic
androgen receptor suppresses hepatocellular carcinoma metastasis
through modulation of cell migration and anoikis. Hepatology.
56:176–185. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Langley RR and Fidler IJ: The seed and
soil hypothesis revisited - the role of tumor-stroma interactions
in metastasis to different organs. Int J Cancer. 128:2527–2535.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liao X, Thrasher JB, Pelling J,
Holzbeierlein J, Sang QX and Li B: Androgen stimulates matrix
metalloproteinase-2 expression in human prostate cancer.
Endocrinology. 144:1656–1663. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shyr CR, Chen CC, Hsieh TF, et al: The
expression and actions of androgen receptor in upper urinary tract
urothelial carcinoma (UUTUC) tissues and the primary cultured
cells. Endocrine. 43:191–199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Heinlein CA and Chang C: Androgen receptor
in prostate cancer. Endocr Rev. 25:276–308. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Niu Y, Altuwaijri S, Lai KP, et al:
Androgen receptor is a tumor suppressor and proliferator in
prostate cancer. Proc Natl Acad Sci USA. 105:12182–12187. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bonaccorsi L, Carloni V, Muratori M, et
al: Androgen receptor expression in prostate carcinoma cells
suppresses alpha6beta4 integrin-mediated invasive phenotype.
Endocrinology. 141:3172–3182. 2000.PubMed/NCBI
|
|
34
|
Niu Y, Altuwaijri S, Yeh S, et al:
Targeting the stromal androgen receptor in primary prostate tumors
at earlier stages. Proc Natl Acad Sci USA. 105:12188–12193. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu JT, Han BM, Yu SQ, Wang HP and Xia SJ:
Androgen receptor is a potential therapeutic target for bladder
cancer. Urology. 75:820–827. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Baldi E, Bonaccorsi L and Forti G:
Androgen receptor: good guy or bad guy in prostate cancer invasion?
Endocrinology. 144:1653–1655. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Miyamoto H, Altuwaijri S, Cai Y, Messing
EM and Chang C: Inhibition of the Akt, cyclooxygenase-2, and matrix
metalloproteinase-9 pathways in combination with androgen
deprivation therapy: potential therapeutic approaches for prostate
cancer. Mol Carcinog. 44:1–10. 2005. View
Article : Google Scholar
|
|
38
|
Coussens LM, Fingleton B and Matrisian LM:
Matrix metalloproteinase inhibitors and cancer: trials and
tribulations. Science. 295:2387–2392. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kirschenbaum A, Liu X-H, Yao S and Levine
AC: The role of cyclooxygenase-2 in prostate cancer. Urology.
58:127–131. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Oku S, Higashi M, Imazono Y, et al:
Overexpression of cyclooxygenase-2 in high-grade human transitional
cell carcinoma of the upper urinary tract. BJU Int. 91:109–114.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jeon HG, Jeong IG, Bae J, et al:
Expression of Ki-67 and COX-2 in patients with upper urinary tract
urothelial carcinoma. Urology. 76:513.e7–513.e12. 2010.PubMed/NCBI
|
|
42
|
Vassilakopoulou M, de La Motte Rouge T,
Colin P, et al: Outcomes after adjuvant chemotherapy in the
treatment of high-risk urothelial carcinoma of the upper urinary
tract (UUT-UC): results from a large multicenter collaborative
study. Cancer. 117:5500–5508. 2011. View Article : Google Scholar
|
|
43
|
Hellenthal NJ, Shariat SF, Margulis V, et
al: Adjuvant chemotherapy for high risk upper tract urothelial
carcinoma: results from the Upper Tract Urothelial Carcinoma
Collaboration. J Urol. 182:900–906. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Miyamoto H, Messing EM and Chang C:
Androgen deprivation therapy for prostate cancer: current status
and future prospects. Prostate. 61:332–353. 2004. View Article : Google Scholar : PubMed/NCBI
|
